Abstracts - faqs.org

Abstracts

News, opinion and commentary

Search abstracts:
Abstracts » News, opinion and commentary

New Drug Regimen Greatly Cuts Risk of Recurring Breast Cancer

Article Abstract:

A large international study has found that letrozole, sold as Femara by Novartis, can significantly reduce the chance of recurrence of breast cancer in postmenopausal women who have taken tamoxifen for five years, after which tamoxifen offers no additional benefits. Results with letrozole were so positive that investigators ended the study early in order to offer letrozole to women in the study who had been taking a placebo. Letrozole was found to reduce the yearly 2 to 4 percent chance of recurrence of cancer by nearly half.

Author: Kolata, Gina
Publisher: The New York Times Company
Publication Name: The New York Times
Subject: News, opinion and commentary
ISSN: 0362-4331
Year: 2003
Product information, Switzerland, Health aspects, Novartis AG, Breast cancer, Women's health, Postmenopausal women, NVTSY, Letrozole, Femara (Medication)

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


GENE THERAPY USED TO TREAT PATIENT WITH PARKINSON'S

Article Abstract:

Dr. Michael G. Kaplitt operated on the first person to receive an injection of 3.5 million viral particles into the brain to control? tremors and muscular dysfunction caused by Parkinson disease. The FDA approved the experimental treatment despite the risk of inhibiting brain cells from the infusion of large quantities of proteins. The surgery was performed at New York-Presbyterian Hospital.

Author: Kolata, Gina, Grady, Denise
Publisher: The New York Times Company
Publication Name: The New York Times
Subject: News, opinion and commentary
ISSN: 0362-4331
Year: 2003
Management dynamics, New York, Care and treatment, Usage, Practice, Gene therapy, Parkinson's disease, Parkinson disease, Viral proteins, Kaplitt, Michael G.

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


A Widely Used Arthritis Drug Is Withdrawn

Article Abstract:

Merck and Company will withdraw the arthritis and pain medication Vioxx because a study has shown that it doubles the risk of heart attack and stroke.

Author: Kolata, Gina
Publisher: The New York Times Company
Publication Name: The New York Times
Subject: News, opinion and commentary
ISSN: 0362-4331
Year: 2004
United States, Pharmaceutical preparations, Product discontinued, Medicinal and Botanical Manufacturing, Medicinals and botanicals, Analgesics & Antipyretics NEC, Complications and side effects, Risk factors, Heart diseases, Stroke (Disease), Stroke, Arthritis, Analgesics, Vioxx (Medication), Product discontinuation, Merck & Company Inc.

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Research, Pharmaceutical industry, Drug therapy
Similar abstracts:
  • Abstracts: Uncertain times: Canada's economy shows signs of cooling. The road back
  • Abstracts: Royal group chairman leads life of jet set. Clitheroe urges hydro reform. Clitheroe steps down from TD's board
  • Abstracts: At Funeral for Hussein Sons, A Call for 'Death to America'. Biggest Task for U.S. General Is Training Iraqis to Fight Iraqis
  • Abstracts: Israel Agrees to Turn Over 2 Cities In West Bank, Aiding Peace Plan. Israelis Worry About Terror, By Jews Against Palestinians
  • Abstracts: OVERSIGHT GROUP WARNED UTILITIES ON POWER FLOWS. Few Indications Efforts to Cut Blackout Risks Are Under Way. Midwest Utilities Were Warned About Pushing Limits of System
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2026 Advameg, Inc.